Table 1. Clinical characteristics of Cohorts 1 and 2.
| Subject code | Disease stage | Age | Gender | Subtype | MRSS | SSc intrinsic subset assignment |
|---|---|---|---|---|---|---|
| Cohort 1 | ||||||
| ssc01LF | Late | 51 | F | dcSSc | 36 | Inflammatory |
| ssc02B LF | Late | 46 | F | dcSSc | 35 | Inflammatory |
| ssc05 BRA | Early | 40 | F | dcSSc | 32 | Inflammatory |
| ssc06BRA | Early | 54 | F | lcSSc | 16 | Inflammatory |
| ssc08BLA | Early | 65 | F | dcSSc | 12 | Inflammatory |
| ssc10BLF | Early | 52 | F | dcSSc | 13 | Inflammatory |
| ssc1004BLA | Late | 27 | F | dcSSc | 26 | Normal-Like |
| ssc1156BLA | Early | 48 | F | SSc/PM | 20 | Inflammatory |
| ssc1213LA | Late | 30 | F | dcSSc | 4 | Inflammatory |
| ssc1002BLA | Late | 34 | F | dcSSc | 32 | Fibroproliferative |
| ssc1103 BLA | Late | 54 | F | dcSSc | 13 | Inflammatory |
| ssc1215LA | Late | 30 | F | dcSSc | 4 | Inflammatory |
| ssc1269LA | Early | 50 | F | dcSSc | 14 | Inflammatory |
| Cohort 2 | ||||||
| SScMH_03_Base_LA | Early | 48 | F | dcSSc | 21 | Inflammatory |
| SScMH_04_Base_LA | Early | 45 | F | dcSSc | 9 | Normal-like |
| SScMH_05_Base_RA | Early | 40 | F | dcSSc | 32 | Inflammatory |
| SScMH_06_Base_RA | Early | 54 | F | lcSSc | 16 | Inflammatory |
| SScMH_08_Base_LA | Early | 65 | F | dcSSc | 12 | Inflammatory |
| SScMH_12_Base_LA | Early | 51 | F | dcSSc | 14 | Fibroproliferative |
| SScMH_13_Base_LA | Early | 57 | F | dcSSc | 17 | Inflammatory |
| SScMH_17_Base_LA | Early | 53 | M | dcSSc | 35 | Inflammatory |
| SScMH_18_Base_LA | Late | 57 | F | dcSSc | 11 | Fibroproliferative |
| SScMH_27_Base_LA | Early | 47 | F | dcSSc | 29 | Inflammatory |
| SScMH_30_Base_LA | Early | 56 | F | dcSSc | 17 | Fibroproliferative |
| SScMH_31_Base_LA | Early | 56 | F | dcSSc | 15 | Inflammatory |
| SScMH_42_Base_LA | Early | 47 | M | dcSSc | 16 | Inflammatory |
| SScReg_1103_Base_LA | Late | 54 | F | dcSSc | 13 | Inflammatory |
| SScMH_13_Base_LA | Early | 57 | F | dcSSc | 17 | Inflammatory |
| SScMH_30_Base_LA | Early | 56 | F | dcSSc | 17 | Fibroproliferative |
| SScMH_44__LA | Early | 68 | F | dcSSc | 12 | Fibroproliferative |
| SScMH_26_Base_LA | Early | 58 | F | dcSSc | 18 | Fibroproliferative |
SSc subjects providing skin biopsy samples (lesional forearm) for RNA and immunofluorescence analysis. dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc; PM, polymyositis overlap; M, male, F, female. *Early, disease duration <2 years from first non-Raynaud disease manifestation; late, >2 years from first non-Raynaud manifestation. MRSS, modified Rodnan skin score (1 to 51). Intrinsic subsets: D, diffuse, inflammatory. For Cohort 1, controls were healthy volunteers (100% female; median age, 47 years; range, 27 to 65 years). For cohort 2, controls were healthy subjects (90% female; median age, 56 years; range, 47 to 68 years).